AML patient results
| Patient no. . | FAB classification . | MRP1 FISH no. signals . | MRP activity* . | P-gp activity† . | Overall survival (m) . | Present status . |
|---|---|---|---|---|---|---|
| 1 | M4Eo | 0 | 1.2 | 1.5 | 11 | relapse |
| 2 | M1 | 0 | 1.6 | 6.5 | — | toxic death |
| 3 | M4Eo | 1 | 2.3 | 2.4 | 26 | CR |
| 4 | M4Eo | 1 | 2.7 | 1.8 | — | toxic death |
| 5 | M4Eo | 1 | 2.3 | 1.8 | — | death in CR |
| 6 | M4Eo | 1 | 1.9 | 1.6 | 74 | CR |
| 7 | M4Eo | 1 | 2.4 | 2.1 | 81 | CR |
| 8 | M4Eo | 2‡ | 3.0 | 1.6 | 95 | CR |
| 9 | M2 | 2‡ | 3.6 | 2.5 | 23 | CR |
| 10 | M4Eo | 2‡ | 2.7 | 1.6 | 14 | CR |
| 11 | M4Eo | 2‡ | 3.3 | 2.2 | — | toxic death |
| NB | 2 | 2.8 ± 0.5 | 1.8 ± 0.4 | |||
| (n = 3) | (n = 9) | (n = 9) |
| Patient no. . | FAB classification . | MRP1 FISH no. signals . | MRP activity* . | P-gp activity† . | Overall survival (m) . | Present status . |
|---|---|---|---|---|---|---|
| 1 | M4Eo | 0 | 1.2 | 1.5 | 11 | relapse |
| 2 | M1 | 0 | 1.6 | 6.5 | — | toxic death |
| 3 | M4Eo | 1 | 2.3 | 2.4 | 26 | CR |
| 4 | M4Eo | 1 | 2.7 | 1.8 | — | toxic death |
| 5 | M4Eo | 1 | 2.3 | 1.8 | — | death in CR |
| 6 | M4Eo | 1 | 1.9 | 1.6 | 74 | CR |
| 7 | M4Eo | 1 | 2.4 | 2.1 | 81 | CR |
| 8 | M4Eo | 2‡ | 3.0 | 1.6 | 95 | CR |
| 9 | M2 | 2‡ | 3.6 | 2.5 | 23 | CR |
| 10 | M4Eo | 2‡ | 2.7 | 1.6 | 14 | CR |
| 11 | M4Eo | 2‡ | 3.3 | 2.2 | — | toxic death |
| NB | 2 | 2.8 ± 0.5 | 1.8 ± 0.4 | |||
| (n = 3) | (n = 9) | (n = 9) |
AML indicates acute myeloid leukemia; FAB, French-American-British; FISH, fluorescent in situ hybridization; m, months; NB, normal bone marrow; CR, complete remission.
Expressed as CF efflux-blocking factor of MK-571.
Expressed as Rh123 efflux-blocking factor of PSC833.
In these cases, 1 MRP1 signal was observed on the q arm of chromosome 16.